Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule treatments for serious diseases including oncology and obesity, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.
The company's senior management will deliver a presentation on Wednesday, February 12, 2025, at 4:00 p.m. ET. Investors and interested parties can access a live webcast of the presentation through the investor relations page at http://ir.ternspharma.com. The presentation recording will remain available on the company's website for a minimum of 30 days following the event.
Terns Pharmaceuticals (Nasdaq: TERN), un'azienda biofarmaceutica in fase clinica focalizzata nello sviluppo di trattamenti a piccole molecole per malattie gravi, tra cui oncologia e obesità, ha annunciato la sua partecipazione alla prossima 35ª Conferenza Annuale sulla Salute e Scienze della Vita di Oppenheimer.
Il team di gestione senior dell'azienda presenterà il suo intervento mercoledì 12 febbraio 2025, alle 16:00 ET. Gli investitori e le parti interessate possono accedere a una diretta del webcast della presentazione attraverso la pagina delle relazioni con gli investitori su http://ir.ternspharma.com. La registrazione della presentazione rimarrà disponibile sul sito web dell'azienda per un minimo di 30 giorni dopo l'evento.
Terns Pharmaceuticals (Nasdaq: TERN), una compañía biofarmacéutica en etapa clínica enfocada en desarrollar tratamientos de pequeñas moléculas para enfermedades graves, incluyendo oncología y obesidad, ha anunciado su participación en la próxima 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer.
La alta dirección de la compañía realizará una presentación el miércoles 12 de febrero de 2025, a las 4:00 p.m. ET. Los inversores y partes interesadas pueden acceder a una transmisión en vivo de la presentación a través de la página de relaciones con los inversores en http://ir.ternspharma.com. La grabación de la presentación estará disponible en el sitio web de la compañía por un mínimo de 30 días después del evento.
Terns Pharmaceuticals (Nasdaq: TERN), 심각한 질병, 특히 종양학 및 비만에 대한 소분자 치료를 개발하는 데 집중하는 임상 단계의 생물 제약 회사가 다음 Oppenheimer 제35회 연례 헬스케어 생명과학 회의에 참여한다고 발표했습니다.
회사의 고위 경영진은 2025년 2월 12일 수요일 오후 4시 ET에 발표를 진행할 예정입니다. 투자자 및 관심 있는 당사자는 http://ir.ternspharma.com의 투자자 관계 페이지를 통해 발표의 라이브 웹캐스트에 접근할 수 있습니다. 발표 녹음은 이벤트 후 최소 30일 동안 회사 웹사이트에서 사용할 수 있습니다.
Terns Pharmaceuticals (Nasdaq: TERN), une entreprise bio-pharmaceutique en phase clinique concentrée sur le développement de traitements à petites molécules pour des maladies graves, y compris l'oncologie et l'obésité, a annoncé sa participation à la prochaine 35e Conférence Annuelle sur les Sciences de la Vie et la Santé d'Oppenheimer.
La direction senior de l'entreprise fera une présentation le mercredi 12 février 2025, à 16h00 ET. Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la page des relations avec les investisseurs sur http://ir.ternspharma.com. L'enregistrement de la présentation restera disponible sur le site web de l'entreprise pendant au moins 30 jours après l'événement.
Terns Pharmaceuticals (Nasdaq: TERN), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von niedermolekularen Behandlungen für schwere Krankheiten, einschließlich Onkologie und Adipositas, konzentriert, hat seine Teilnahme an der bevorstehenden 35. jährlichen Gesundheits- und Lebenswissenschaftskonferenz von Oppenheimer angekündigt.
Das obere Management des Unternehmens wird am Mittwoch, den 12. Februar 2025, um 16:00 Uhr ET eine Präsentation halten. Investoren und Interessierte können über die Investor-Relations-Seite unter http://ir.ternspharma.com auf einen Livestream der Präsentation zugreifen. Die Aufzeichnung der Präsentation wird für mindestens 30 Tage nach der Veranstaltung auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
FOSTER CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025 at 4:00 p.m. ET.
A live webcast of the event will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for at least 30 days following the presentations.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com.
Contacts for Terns
Investors
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com
FAQ
When is Terns Pharmaceuticals (TERN) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch Terns Pharmaceuticals' (TERN) Oppenheimer Conference presentation?
How long will Terns Pharmaceuticals' (TERN) Oppenheimer Conference presentation be available for replay?
What therapeutic areas is Terns Pharmaceuticals (TERN) focusing on in 2025?
